Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Asuragen Team on MDx Kits

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today said that it has signed a collaboration with Affymetrix to develop RNA Control Kits for molecular diagnostic applications.

Under the agreement, Asuragen will develop and manufacture the kits, which are intended for use with in vitro transcription reagent kits for clinical molecular diagnostic applications, for Affymetrix. The Austin, Texas-based firm said that the kits will enable Affy to supply its molecular diagnostic partners with complete solutions.

In addition, Asuragen noted that the RNA Control Kits will be configured for use on Affy's GeneChip System 3000Dx v.2, which has 510(k) clearance from the US Food and Drug Administration and has the CE Mark in the European Union. The kits make use of Asuragen's expertise in developing and manufacturing multiplexed IVT RNA reagents for use as internal controls, the firm told GenomeWeb Daily News via e-mail.

Asuragen also noted that there are currently more than 20 different molecular assays based on the Affymetrix platform under development by Affymetrix and the 11 partners in its "Powered by Affymetrix" program.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.